# Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients

> **NCT05039190** · PHASE3 · COMPLETED · sponsor: **Harbour BioMed (Guangzhou) Co. Ltd.** · enrollment: 132 (actual)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **DRUG:** HBM9161 Injection (680mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05039190
- **Lead sponsor:** Harbour BioMed (Guangzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-25
- **Primary completion:** 2023-01-14
- **Final completion:** 2023-01-14
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2023-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05039190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05039190, "Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05039190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*